A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Reference |
|---|
| "Oxacillin-induced neutropenia is reported in a 16-year-old boy being treated for osteomyelitis." | ( Passoff, TL; Sherry, HS, 1978) |
| "Neutropenia is the dose-limiting toxicity, and 1." | ( Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Hurowitz, LA; Kaufmann, SH; Lubejko, BG; McGuire, WP; Rowinsky, EK; Sartorius, SE, 1992) |
| "Neutropenia is a recognized complication of sulphasalazine therapy in patients with rheumatoid arthritis." | ( Chakravarty, K; McCann, BG; Scott, DG, 1992) |
| "Cyclic neutropenia is a rare hematological disorder consisting of recurrent episodes of aphthous stomatitis and skin infections caused by a periodic decrease in blood neutrophil counts." | ( Herranz, MT; Ortego, N; Pinar, A; Quero, JH; Ródenas, JM; Tercedor, J, 1992) |
| "Neutropenia is of considerable clinical relevance because it can be a sign of incipient agranulocytosis." | ( Barnas, C; Fleischhacker, WW; Hummer, M; Kurz, M, 1992) |
| "Neutropenia is a major cause of chemotherapy-induced morbidity." | ( Hindahl, M; Huang, HS; Jimenez, JJ; Pearson, FC; Yunis, AA, 1992) |
| "Neutropenia is an uncommon but potentially serious complication of drug therapy." | ( John, PG; Walbroehl, GS, 1992) |
| "Neutropenia is likely to have contributed to the development of pyomyositis in these patients." | ( French, MA; Thomas, R, 1991) |
| "Since neutropenia is common during cancer treatment, there is a continual risk of infection in cancer patients; thus it is important for medical oncologists to become aware of these complications and their management." | ( Fujimoto, T, 1986) |
| "Leukopenia and/or neutropenia are thought to be characteristic findings in patients with typhoid fever." | ( Mallouh, AA; Sa'di, AR, 1987) |
| "Neutropenia is a potentially serious complication of parenteral benzylpenicillin administration." | ( Al-Hadramy, MS; Aman, H; Khan, MA; Omer, A, 1986) |
| "Neutropenia is a life-threatening sequel of hematological disorders and a dominant factor limiting the dosage of cytotoxic chemotherapy." | ( Firkin, FC, 1985) |
| "Neutropenia is an occasional complication of treatment with cephalosporin antibiotics." | ( Amess, JA; Green, AR; Grint, PC; Knowles, S; Metcalfe, P; Murphy, MF; Waters, AH, 1985) |
| "Neutropenia is rarely associated with cephalosporins." | ( Furukawa, F; Ohsawa, T, 1983) |
| "Benign neutropenia is often found among healthy Yemenite Jews." | ( Berliner, S; Kaufman, C; Lusky, A; Neri, A; Pinkhas, J; Shindel, D; Shoenfeld, Y, 1983) |
| "Neutropenia is a rare complication of procainamide therapy." | ( Ellrodt, AG; Gray, R; Mochizuki, C; Murata, GH; Riedinger, MS; Stewart, ME, 1984) |
| "Neutropenia is the dose limiting toxicity." | ( Fumoleau, P; Lemevel, B; Maugard-Louboutin, C; Perrocheau, G, 1995) |
| "Neutropenia is the dose-limiting toxicity on both schedules and 750 mg/m2 and 150 mg/m2/d are the recommended starting doses of PZA on single- and multiple-dosing schedules, respectively, for minimally pretreated patients in phase II studies; slightly lower doses are recommended for more heavily pretreated subjects." | ( Bowling, MK; Chen, TL; Donehower, RC; Grochow, LB; Kaufmann, SH; Lubejko, BG; Noe, DA; Rowinsky, EK; Sartorious, SE, 1995) |
| "Drug-induced neutropenia is serious and at times life-threatening." | ( Farver, DK; Hansen, LA, 1994) |
| "Instead, neutropenia is the principal toxicity of paclitaxel." | ( Arbuck, SG; Chaudhry, V; Donehower, RC; Eisenhauer, EA; Rowinsky, EK, 1993) |
| "Neutropenia is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, captopril." | ( Baylen, BG; Cyran, SE; Gleason, MM; Myers, JL; Roloff, JS; Weber, HS, 1993) |
| "Neutropenia is associated with the use of NSAIDs." | ( Carson, JL; Lundin, FE; Schinnar, R; Shaw, M; Snyder, ES; Strom, BL, 1993) |
| "Neutropenia is an important side effect of ganciclovir use and is associated with an increased risk for bacterial infection." | ( Bowden, RA; Fisher, L; Goodrich, JM; Keller, C; Meyers, JD; Schoch, G, 1993) |
| "In conclusion, neutropenia is the most frequent toxicity of this novel combination." | ( Baldini, E; Biadi, O; Conte, PF; DaPrato, M; Gentile, A; Giannessi, PG; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C, 1996) |
| "Neutropenia is the most frequent toxicity and occurs less frequently with the 3-hour infusion." | ( Bunn, PA, 1996) |
| "Neutropenia is the major toxicity, and consideration should be given to the use of prophylactic oral antibiotics or colony stimulating factors to try and prevent febrile episodes." | ( Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC, 1997) |
| "Neutropenia is the most common toxicity associated with mitoxantone therapy and may necessitate dosage reduction in some patients." | ( Spencer, CM; Wiseman, LR, 1997) |
| "Febrile neutropenia is the major dose-limiting toxicity of docetaxel; the neutropenia nadir typically has an early onset and short duration, with rapid recovery of the neutrophil count." | ( Valero, V, 1997) |
| "Neutropenia is a significant adverse effect and pancytopenia is rarely reported." | ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| "Neutropenia is a major adverse effect of cancer chemotherapy and sometimes causes life-threatening events." | ( Kato, Y; Kondo, M; Noda, K; Nomura, I; Oshita, F; Yamada, K, 1999) |
| "Neutropenia is the dose-limiting toxicity of docetaxel in children." | ( Balis, FM; Blaney, SM; Hutchinson, R; Krailo, M; Mosher, RB; O'Brien, M; Reaman, GH; Seibel, NL, 1999) |
| "Cyclic neutropenia is a rare hematologic disorder of unknown origin." | ( Djawari, J; Sucker, C, 1999) |
| "Neutropenia is a common and often dose limiting side effect of some chemotherapy regimens." | ( Armstrong, NA; Bolton, EJ; Morris, DL, 1999) |
| "Neutropenia is the main toxicity." | ( Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A, 2000) |
| "Neutropenia is an important complication of high-dose chemotherapy (HDCT)." | ( Egerer, G; Ehrhard, I; Goldschmidt, H; Haas, R; Hegenbart, U; Ho, AD; Salwender, H, 2000) |
| "Febrile neutropenia is a heterogeneous condition." | ( Armada, AA; Casimir, L; De Martino, MG; Debbag, R; Fernandez, C; Paganini, HR; Rodriguez-Brieshcke, MT; Sarkis, CM; Zubizarreta, PA, 2000) |
| "Grade 4 neutropenia is frequent and G-CSF support is often required." | ( Casella, G; Costanzo, R; De Placido, G; De Vivo, R; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Tramontana, F; Tramontana, S; Varriale, E; Vernaglia, A, 2000) |
| "Neutropenia is an uncommon adverse effect associated with prolonged vancomycin therapy." | ( Dust, WN; Sanche, SE; Shevchuk, YM, 2000) |
| "Neutropenia is the DLT of the new aza-anthracenedione BBR 2778." | ( Bernareggi, A; Borchmann, P; Camboni, GM; Diehl, V; Engert, A; Hübel, K; Knippertz, R; Schnell, R; Schulz, A; Staak, JO; Staib, P, 2001) |
| "Diarrhea and neutropenia are the DLT of this regimen." | ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Neutropenia is likely to occur with synchronous carboplatin/etoposide and radiation in this population of patients." | ( Ainslie, J; Hamilton, C; Harvey, J; Keller, J; Macintosh, J; Poulsen, M; Rischin, D; Tripcony, L; Walpole, E, 2001) |
| "Neutropenia is frequent and severe at A/C 60/600 and need to be watched out for." | ( Baraza, R; Nyabola, LO; Nyong'o, AO; Othieno-Abinya, NA, 2001) |
| "Neutropenia is common in patients receiving myelotoxic chemotherapy." | ( Brassard, M; Budman, DR; Cohen, G; Dhami, M; George, T; Glaspy, J; Hackett, J; Holmes, FA; Jones, SE; Liang, BC; Meza, L; O'Shaughnessy, J; Richards, D; Savin, M; Vukelja, S; Yang, BB, 2002) |
| "Unfortunately, neutropenia is common." | ( Andresen, SW; Avery, RK; Bernhard, L; Bolwell, BJ; Goormastic, M; Kalaycio, ME; Kuczkowski, E; Longworth, DL; Mossad, SB; Ostendorf, H; Pohlman, BL; Sobecks, RM; Wise, K, 2002) |
| "In conclusion, neutropenia is frequent during treatment of hepatitis C with interferon and ribavirin, but it is not usually associated with infection." | ( Doo, E; Everhart, JE; Ghany, MG; Heller, T; Hoofnagle, JH; Liang, TJ; Park, Y; Promrat, K; Soza, A, 2002) |
| "Congenital neutropenia is characterized by a severe reduction in absolute neutrophil counts, resulting in an almost total absence of neutrophils." | ( Berker, E; Ersoy, F; Sanal, O; Tezcan, I; Tözüm, TF, 2003) |
| "Febrile neutropenia is a common and potentially fatal problem encountered in cancer patients undergoing chemotherapy." | ( Jamal, R; Latiff, Z; Zulkifli, SZ, 2002) |
| "Any additional neutropenia is likely to be of brief duration." | ( Jennens, R; Millward, M; Rischin, D; Toner, G; Yuen, K, 2003) |
| "Neutropenia is a common laboratory finding in systemic lupus erythematosus (SLE)." | ( Arimura, K; Eiraku, N; Higashimoto, I; Kawabata, M; Machida, K; Matsuyama, W; Oonakahara, K; Osame, M; Watanabe, M; Yamamoto, M; Yoshimura, T, 2004) |
| "Neutropenia is a rare complication of anti-tuberculous therapy and is usually due to a single agent, most frequently isoniazid." | ( Cormican, LJ; Milburn, HJ; Schey, S, 2004) |
| "Delayed-onset neutropenia is a newly recognised toxicity of rituximab treatment which may last up to one year and be complicated by serious infections." | ( Hofer, S; Ludwig, C; Viollier, R, 2004) |
| "As the duration of neutropenia is the strongest predictor of survival in neutropenic patients with invasive fungal infections, neutrophil transfusions are a logical, therapeutic option." | ( Collins, M; Edwards, JE; French, SW; Fu, Y; Ibrahim, AS; Spellberg, BJ, 2005) |
| "Neutropenia is the most frequent side effect of cotrimoxazole in sub-Saharan Africa." | ( Anglaret, X; Anzian, A; Bissagnene, E; Danel, C; Gabillard, D; Gomis, OB; Inwoley, A; Konga, C; Minga, A; Moh, R; Salamon, R; Sauvageot, D; Sorho, S, 2005) |
| "Beta-lactam-induced neutropenia is frequently preceded by fever or rash, which can be considered alarm signs." | ( Peralta, G; Sánchez-Santiago, MB, 2005) |
| "Neutropenia is an indicator of poor prognosis in patients with fungal infections." | ( Betts, R; Glasmacher, A; Kartsonis, N; Lupinacci, R; Maertens, J; Maschmeyer, G; Sable, C; Taylor, A; Teppler, H; Vazquez, JA, 2006) |
| "Febrile neutropenia is one of the most frequent complications in intensively treated hematooncological patients and almost inevitably occurs after high dose therapy and autologous stem cell transplantation." | ( Hnátková, M; Jedlicková, A; Klener, P; Trnený, M; Vacková, B; Zikesoá, E, 2006) |
| "Neutropenia is a severe adverse effect that can occur when treating patients with imatinib mesylate for advanced-stage chronic myelogenous leukaemia (CML)." | ( Asaka, M; Hashino, S; Imamura, M; Kondo, K; Matsuno, K; Mori, A; Musashi, M; Onozawa, M; Ota, S; Tanaka, J; Toubai, T; Toyoshima, N, 2006) |
| "Leukopenia and neutropenia are recognised as side effects of antipsychotic medication, notably clozapine." | ( Cowan, C; Oakley, C, 2007) |
| "Treatment-related neutropenia is caused primarily by interferon or peginterferon." | ( Dar Santos, AE; Ford, JA; Partovi, N; Yoshida, EM, 2007) |
| "Febrile neutropenia is an expected complication during treatment of aggressive hematological malignancies and hematopoietic cell transplantation." | ( Craig, M; Cumpston, AD; Devetten, MP; Ericson, SG; Hobbs, GR; Sarwari, AR, 2007) |
| "Severe Congenital Neutropenia is a rare condition characterized by a very low neutrophil count, which pre-disposes the affected child to recurrent bacterial infections." | ( Bolton-Maggs, PH; Caswell, M; Keenan, R; Pizer, B; Thachil, J, 2008) |
| "Neutropenia is a major risk factor for developing a serious infection." | ( Balkis, M; Hela, BA; Karima, K; Lamia, A; Mohamed, Z; Raihane, B; Ramzi, J; Yosr, B; Zaher, B, 2007) |
| "Neutropenia is uncommon." | ( Khiewyoo, J; Krisanaprakornkit, T; Maskasame, S, 2007) |
| "Although neutropenia is generally mild in severity, potentially severe DVPX-associated neutropenia can occur any time during the course of therapy, although it is most common within the first few months of treatment." | ( Deal, E; Lurk, JT; Stoner, SC, 2008) |
| "Neutropenia is one major side-effect of many antitumor agents, and is related to an increased risk of infection." | ( Friberg, LE; Karlsson, MO; Wallin, JE, 2009) |
| "Neutropenia is a frequent complication associated with MMC-HIPEC." | ( Armstrong, TS; Eng, C; Gonzalez-Moreno, S; Katz, MH; Lambert, DH; Lambert, LA; Lee, JJ; Liu, S; Mansfield, PF; Tansey, P; Tortorice, ML; Wolff, RA, 2009) |
| "Neutropenia is an important and frequent laboratory finding that may exert a significant influence on outcomes in kidney transplantation." | ( Anglicheau, D; Bergougnoux, L; Ciroldi, M; Etienne, D; Kreis, H; Lechaton, S; Legendre, C; Mamzer, MF; Martinez, F; Rafat, C; Snanoudj, R; Thervet, E; Timsit, MO; Truffaut, L; Zafrani, L; Zuber, J, 2009) |
| "Late-onset neutropenia is intriguing biologically and while its pathogenesis and mechanism are not completely understood, many interesting hypotheses have been proposed to explain its occurrence." | ( Dunleavy, K; Tay, K; Wilson, WH, 2010) |
| "Tacrolimus-induced neutropenia is a less recognized, but potentially harmful complication." | ( De Rycke, A; Dierickx, D; Kuypers, DR, 2011) |
| "Vancomycin-induced neutropenia is most likely associated with prolonged vancomycin exposure." | ( Black, E; Ensom, MH; Lau, TT, 2011) |
| "Neutropenia is the most common cause for Peg-IFN dose reduction." | ( Doucette, K; Dryden, DM; Durec, T; Fassbender, K; Tandon, P; Vandermeer, B, 2011) |
| "Neutropenia is the most common collateral effect of chemotherapy." | ( Alvarez-Silva, M; Asbahr, AC; Benedetti, AL; Bertol, G; Dalmora, SL; do Carmo Araújo, M; Farias, I; Farias, J; Schetinger, MR; Zimmermann, ES, 2011) |
| "Neutropenia is frequent during treatment of chronic hepatitis C (CHC) with peginterferon and ribavirin." | ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2011) |
| "Chronic neutropenia is a myeloid hematologic disorder with a broad spectrum of etiological factors." | ( Masri, DS, 2011) |
| "Severe neutropenia is the most frequent and important toxicity of 3-weekly paclitaxel and puts patients at substantial risk of infectious complications." | ( Beijnen, JH; Feiss, G; Huitema, AD; Jaehde, U; Joerger, M; Kraff, S; Moritz, B; Schellens, JH, 2012) |
| "Neutropenia is one of the most frequent and dose-limiting toxicities in amrubicin (AMR) therapy." | ( Egashira, N; Harada, T; Ikesue, H; Mishima, K; Nagata, K; Nakanishi, Y; Oishi, R; Oshiro, M; Suetsugu, K; Sueyasu, M; Takada, A; Takayama, K; Watanabe, H, 2012) |
| "Neutropenia is a rare side effect of gefitinib and was scarcely reported in many large-scale randomized phase III trials using gefitinib monotherapy as first-line treatment." | ( Araya, T; Demura, Y; Kasahara, K; Matsuoka, H; Nishi, K; Nishitsuji, M, 2013) |
| "Although neutropenia is a potential cephalosporin class effect, we present the first case of neutropenia directly related to ceftaroline." | ( Cook, PP; Frenkel, A; Rimawi, RH, 2013) |
| "Neutropenia is one of the major dose-limiting adverse effects of eribulin." | ( Beijnen, JH; Gupta, A; Huitema, AD; Hussein, Z; Schellens, JH; van Hasselt, JG, 2013) |
| "Febrile neutropenia is a major toxicity of myelosuppressive chemotherapy." | ( Kubeček, O, 2013) |
| "Neutropenia is common to both Hermansky-Pudlak syndrome type 2 and canine cyclic hematopoiesis (CH) which are caused by mutations in the AP3B1 gene." | ( Christopherson, P; Hock, T; Lothrop, CD; Niemeyer, GP; Urie, B; Vaglenov, A; Vallejo, MO, 2013) |
| "Neutropenia is a common adverse effect of the treatment of chronic hepatitis C with pegylated interferon and ribavirin." | ( Cao, ZH; Chen, XY; Du, XF; Guo, DD; Liu, YL; Lu, JF; Ma, LN; Zhang, YH, 2013) |
| "Neutropenia is a life-threatening side effect of irinotecan, and uridine diphosphate glucuronosyltransferases (UGTs) gene polymorphisms are considered to be one of the predictive markers of irinotecan-related toxicities." | ( An, GY; Gong, LL; Guo, CL; Han, FF; Li, GR; Liu, H; Liu, LH; Lv, YL; Yu, D; Zhu, J, 2014) |
| "Febrile neutropenia is an oncologic emergency that can result in serious consequences." | ( Copeland, L; Li, Q; Romeo, C, 2015) |
| "Neutropenia is a major dose-limiting toxicity associated with lenalidomide in relapsed/refractory multiple myeloma (MM)." | ( Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Sun, HL; Trudel, S; Winter, A; Yeboah, E, 2015) |
| "Neutropenia is a severe adverse-event of chemotherapeutics." | ( Friberg, LE; Karlsson, MO; Lindman, H; Quartino, AL, 2014) |
| "Neutropenia is a common chemotherapy-derived complication in cancer patients, in whom the prevalence of sepsis ranges from 12." | ( Huelgas-Plaza, AC; Miranda-Novales, MG; Pacheco-Rosas, DO, 2014) |
| "Neutropenia is one of the most important dose-limiting toxicities of docetaxel." | ( Daimon, T; Eto, T; Hatori, M; Hayashi, H; Ikeda, M; Inoue, K; Itoh, K; Kamezato, M; Taku, K; Tsuji, D, 2013) |
| "Although neutropenia is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors." | ( Chung, KH; Tang, HC, 2014) |
| "Neutropenia is a major dose-limiting side effect of chemotherapy and is closely related to febrile neutropenia which mainly occurs during the first cycle." | ( Chatelut, E; Concordet, D; Gladieff, L; Laffont, CM; Pastor, ML, 2015) |
| "Neutropenia is the most commonly encountered systemic toxicity and in this study we aimed to determine the risk factors associated with the development of severe (≥ grade 3) neutropenia." | ( Abramson, DH; Brodie, SE; Dunkel, IJ; Gobin, YP; Marr, BP; Salvaggio, K; Shi, W, 2014) |
| "Neutropenia is a frequent and severe adverse event in patients receiving paclitaxel chemotherapy." | ( Jaehde, U; Joerger, M; Kraff, S; Lindauer, A; Salamone, SJ, 2015) |
| "Neutropenia is a frequent complication associated with MMC-HIPEC." | ( Brigand, C; Brumaru, D; Kemmel, V; Lessinger, JM; Mercoli, HA; Meyer, N; Romain, B, 2015) |
| "Although severe neutropenia is often observed during this combination therapy, its predictive factors are unknown." | ( Chikamori, A; Egashira, N; Harada, T; Hirano, M; Ikeda, M; Ikesue, H; Iwama, E; Masuda, S; Nakanishi, Y; Ryokai, Y; Suetsugu, K; Takayama, K; Watanabe, H; Yamada, T, 2015) |
| "IFN-I-induced neutropenia is one reason for the impaired bacterial control; however there is evidence that more frequent bacterial infections during IFN-α-treatment occur independently of neutropenia." | ( Duhan, V; Futerman, AH; Gulbins, E; Hardt, C; Häussinger, D; Hoffmann, D; Honke, N; Khairnar, V; Knuschke, T; Lang, F; Lang, KS; Lang, PA; Merches, K; Navarini, AA; Recher, M; Shaabani, N; Tümmler, B; Westendorf, AM, 2015) |
| "Neutropenia is a rare serious adverse event for the class of cephalosporins; however, we observed several cases of severe neutropenia in our outpatient infectious disease practice believed to be associated with ceftaroline use." | ( Anderson, SW; LaVie, KW; O'Neal, CS; O'Neal, HR; Rice, TW; Saavedra, TC, 2016) |
| "However, neutropenia is a frequent associated adverse effect leading to a decrease in the ganciclovir dose or discontinuation of the therapy, thereby favouring viral resistance." | ( Alain, S; Billat, PA; Essig, M; Marquet, P; Neely, M; Picard, N; Saint-Marcoux, F; Sauvage, FL; Woillard, JB, 2016) |
| "Neutropenia is a well-known dose-limiting toxicity associated with lenalidomide plus dexamethasone treatment in patients with multiple myeloma; however, little is known about its management and associated outcomes in the real world setting." | ( Cooney, J; Gray, D; Greil, R; Leleu, X; Minarik, J; O'Gorman, P; Sanz, RG; Szabo, Z; Terpos, E; Williams, C, 2016) |
| "Neutropenia is a major adverse event of docetaxel-based chemotherapy." | ( Gondo, T; Hirasawa, Y; Horiguchi, Y; Nakagami, Y; Nakashima, J; Namiki, K; Ohno, Y; Ohori, M; Sugihara, T; Tachibana, M; Takizawa, I, 2017) |
| "Neutropenia is a common dose-limiting toxicity associated with irinotecan treatment." | ( Baldwin, RM; Innocenti, F; Kroetz, DL; Li, M; Ramirez, J; Ratain, MJ; Seiser, EL, 2018) |
| "Neutropenia is the most commonly reported hematologic toxicity following treatment with palbociclib, a cyclin-dependent kinase 4/6 inhibitor approved for metastatic breast cancer." | ( DeMichele, A; Finn, RS; O'Dwyer, PJ; Ruiz-Garcia, A; Schwartz, GK; Shapiro, GI; Sun, W; Wang, D, 2017) |
| "Neutropenia is a life-threatening side effect of irinotecan, and UDP glucuronosyltransferases (UGTs) gene polymorphisms could predict the side effects in cancer patients and then reduce IRI-induced toxicity by preventative treatment or a decrease in dose." | ( Chen, XM; Kong, SJ; Yin, JF; Zhang, HY; Zhang, J; Zhang, X, 2017) |
| "Neutropenia is linked to the development of invasive candidiasis/candidaemia, for which micafungin has demonstrated efficacy, but evidence in patients with neutropenia is limited." | ( Azie, N; Chandrasekar, P; Hsu, JW; Ruhnke, M; Seibel, NL; Sirohi, B; Wu, C, 2018) |
| "However, severe neutropenia is often observed (40%) during this therapy." | ( Kawachi, S; Kimura, M; Shinoda, Y; Usami, E; Yoshimura, T, 2018) |
| "Neutropenia is a less frequent side effect of aripiprazole." | ( Chaudhary, AM; Felin, T; Naveed, S, 2018) |
| "Neutropenia is a common side effect associated with docetaxel use." | ( Buttigliero, C; Di Maio, M; Di Stefano, RF; Guglielmini, P; Lacidogna, G; Leone, G; Numico, G; Pignataro, D; Scagliotti, GV; Tucci, M; Vignani, F; Zichi, C, 2018) |
| "Docetaxel-induced neutropenia is associated with better survival of mCRPC." | ( Buttigliero, C; Di Maio, M; Di Stefano, RF; Guglielmini, P; Lacidogna, G; Leone, G; Numico, G; Pignataro, D; Scagliotti, GV; Tucci, M; Vignani, F; Zichi, C, 2018) |
| "Neutropenia is a hematologic disorder commonly reported in patients with chronic hepatitis C viral (HCV) infection." | ( Hindi, NN; Saleh, MI, 2018) |
| "Neutropenia is associated with low bone mass, but the underlying mechanisms are poorly characterized." | ( Brunk, S; Geissler, S; Klaassen, S; Klein, C; Kornak, U; Kühnisch, J; Lekaj, A; Mundlos, S; Schinke, T; Seitz, S; Stumpp, S; Textor, M, 2018) |
| "Neutropenia is the most common adverse event and an important factor impacting chemotherapy continuation." | ( Aisu, N; Daibo, K; Hasegawa, S; Kajitani, R; Kiyomi, F; Komono, A; Matsumoto, Y; Munechika, T; Sakamoto, R; Yoshida, Y, 2018) |
| "Neutropenia is commonly observed, and thus stringent treatment guidelines regarding complete blood count (CBC) monitoring have been developed." | ( Aslam, R; Deac, O; Kennedy, J; O'Dwyer, R; Sukor, S; Tierney, A; Watson, GA, 2019) |
| "Prolonged severe neutropenia is one of the most severe toxicities and contributes to potentially life-threatening infections and failure of ASCT." | ( Badawi, M; Cho, YK; Dauki, A; Fernandez, S; Hade, EM; Hofmeister, CC; Irby, DJ; Lamprecht, M; Li, J; Mould, DR; Phelps, MA; Poi, M; Rosko, AE; Sborov, DW, 2018) |
| "Neutropenia is a major risk factor for opportunistic infections in patients with acute myeloid leukemia (AML) who undergo chemotherapy." | ( Ashizawa, M; Fujiwara, SI; Hatano, K; Kako, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Kimura, SI; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Sato, K; Shirato, Y; Toda, Y; Yamamoto, C; Yamasaki, R, 2019) |
| "Neutropenia is a dose-limiting adverse effect of palbociclib and ribociclib." | ( Cersosimo, RJ, 2019) |
| "However, neutropenia is a common reason for dose reductions, leading to concerns about palbociclib efficacy at lower doses." | ( Berger, MJ; Li, J; Lustberg, M; Noonan, A; Ramaswamy, B; Reinbolt, R; Sardesai, S; Schickli, MA; Stover, DG; VanDeusen, J; Vargo, CA; Wesolowski, R; Wilkie, J; Williams, N, 2020) |
| "Neutropenia is a prominent feature in cases of human T-cell LGLL but is normally absent in canine CLL." | ( Museux, K; Rodriguez Piñeiro, I; Rosenberg, D; Turinelli, V, 2019) |
| "Neutropenia is one of the most common dose-limiting toxocities associated with anticancer drug therapy." | ( Boras, B; Chen, W; D'Argenio, DZ; Hu, W; Spilker, ME; Sung, T; Wang, D; Yu, Y; Zheng, J, 2020) |
| "However, neutropenia is associated with high morbidity and mortality due to infection complications." | ( Boegeholz, J; Brueggen, CS; Dimitriou, F; Dummer, R; Haralambieva, E; Manz, MG; Pauli, C; Widmer, CC, 2020) |
| "Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chemotherapy." | ( Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Matsuzawa, H; Mochizuki, N; Nomura, H; Tsuji, D; Yano, T, 2020) |
| "For drugs where neutropenia is dose limiting, neutrophil counts might be used for monitoring drug effect and for dosing optimisation." | ( Aarons, L; Lombard, A; Mistry, H; Ogungbenro, K, 2021) |
| "Neutropenia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy." | ( Aieta, M; Catalano, M; Conca, R; D'Angelo, A; Dreoni, L; Gasperoni, S; Ianza, A; Mini, E; Nobili, S; Petrioli, R; Ramello, M; Roviello, G, 2020) |
| "Drug-induced neutropenia is a well-documented adverse reaction of β-lactam antibiotics, with an incidence of approximately 10% following at least 2 weeks of intravenous therapy." | ( Allos, BM; Cimino, C; Phillips, EJ, 2021) |
| "Neutropenia is the primary risk factor implicated in IPA; however, IPA also occurs in patients without neutropenia, namely, those who are immunosuppressed owing to long-term corticosteroid use." | ( Feng, C; Li, C; Zhang, J; Zhang, M; Zhang, S; Zhou, J, 2021) |
| "The occurrence of neutropenia is associated with high histological response in solid tumors, and it might be associated with tumor shrinkage after DCF therapy." | ( Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Nomura, H; Tsuji, D; Ueno, S; Yano, T, 2022) |
| "Neutropenia is a dose-related treatment-limiting and costly adverse event of pemetrexed." | ( Boosman, RJ; Burger, DM; de Boer, M; de Rouw, N; Derijks, HJ; Frederix, GWJ; Lieverse, JE; Ter Heine, R; van den Heuvel, MM, 2022) |
| "Severe neutropenia is the major dose-liming toxicity of irinotecan-based chemotherapy." | ( Bies, RR; Forrest, A; Innocenti, F; Karas, S; Mathijssen, RHJ; van Schaik, RHN; Wiltshire, T, 2022) |
| "Neutropenia is the main cause of treatment suspension, delay, and/or dose reductions, also leading to relative dose intensity reduction." | ( Dosaka-Akita, H; Kinoshita, I; Noguchi, T; Saito, Y; Shimizu, Y; Sugawara, M; Takekuma, Y; Takeshita, T; Takeuchi, S, 2022) |
| "Neutropenia is a major dose-limiting toxicity of cancer chemotherapy." | ( Fermanelli, V; Kasai, H; Otani, Y; Poppenberg, KL; Tanigawara, Y, 2023) |
| "Neutropenia is the most common adverse event with palbociclib, an oral cyclin-dependent kinase 4/6 inhibitor, with grade 3/4 neutropenia occurring in up to 67% of patients in phase III trials evaluating this agent in metastatic breast cancer." | ( DiSogra, K; Heeke, A; Lavery, L; Lea, J; Moore, DC; Pal, S; Roberts, A; Symanowski, JT; Trufan, SJ, 2022) |
| "Neutropenia is the most common adverse event (AE) of palbociclib, an oral CDK4/6 inhibitor for breast cancer." | ( Chen, R; Jian, W; Wang, M; Xue, J; Yao, Q; Yao, Y; Zhou, T, 2022) |
| "Drug-induced neutropenia is the main reason for the dose limitation of docetaxel in patients with breast cancer." | ( Chen, Q; Chen, Y; Guo, J; Li, X; Lin, J; Lin, M; Lin, W; Weng, Y; Yu, X; Zeng, S; Zheng, X, 2022) |
| "Drug-induced neutropenia is the main reason for the dose limitation of docetaxel in patients with breast cancer." | ( Chen, Q; Chen, Y; Guo, J; Li, X; Lin, J; Lin, M; Lin, W; Weng, Y; Yu, X; Zeng, S; Zheng, X, 2022) |
| "Drug-induced neutropenia is the main reason for the dose limitation of docetaxel in patients with breast cancer." | ( Chen, Q; Chen, Y; Guo, J; Li, X; Lin, J; Lin, M; Lin, W; Weng, Y; Yu, X; Zeng, S; Zheng, X, 2022) |
| "Neutropenia is a classical risk factor for fungal infections, while critically ill patients in the ICU are now increasingly at risk of yeast and mould infections." | ( Azoulay, E; Maertens, J; Pagano, L; Warris, A, 2022) |
| "Neutropenia is a classical risk factor for fungal infections, while critically ill patients in the ICU are now increasingly at risk of yeast and mould infections." | ( Azoulay, E; Maertens, J; Pagano, L; Warris, A, 2022) |
| "Neutropenia is a classical risk factor for fungal infections, while critically ill patients in the ICU are now increasingly at risk of yeast and mould infections." | ( Azoulay, E; Maertens, J; Pagano, L; Warris, A, 2022) |
| "Neutropenia is a noteworthy side effect of clozapine, which might warrant this drugs' discontinuance for safety." | ( Chou, PH; Lin, CH; Wang, XY; Yang, CC, 2023) |
| "Severe neutropenia is a life-threatening event characterized by a sharp drop in absolute neutrophil count." | ( AlAboud, M; Alanizi, A; Alasqah, MA; Alhubaishi, AA; Alkahtani, R; Alnajjar, LI; Alwahhabi, B; Bin Sheraim, N, 2023) |
| "Neutropenia is an essential finding in GSD 1b and responsible for complications." | ( Bilginer Gürbüz, B; Engin Erdal, A; Kasapkara, ÇS; Küçükçongar Yavaş, A; Ünlüsoy Aksu, A, 2023) |
| "Neutropenia is the most important cause of life-threatening invasive fungal infections (IFIs)." | ( Abdollahzadeh, H; Aghebati-Maleki, A; Aghebati-Maleki, L; Hasani, A; Hassanpour, P; Morovati, H; Nami, S; Raeisi, M; Rezaee, MA; Spotin, A, 2023) |